SERA News and Press, Sera Prognostics Inc. From 03/18/22

Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting PR Newswire SALT LAKE CITY , March 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company...

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29 PR Newswire SALT LAKE CITY , March 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SER...

The following slide deck was published by Sera Prognostics, Inc. in conjunction with this event. For further details see: Sera Prognostics (SERA) Investor Presentation - Slideshow

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES PR Newswire SALT LAKE CITY , March 3, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by prov...

SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE PR Newswire SALT LAKE CITY , Feb. 17, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal...

SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES PR Newswire SALT LAKE CITY , Feb. 7, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health b...

Sera Prognostics (SERA +3.7%) has signed an agreement with MultiPlan to join its PHCS and MultiPlan Networks to widen the patient access to the company’s PreTRM Test, a blood-based biomarker test to predict spontaneous preterm birth. PreTRM Test allows the clinicians to accurately iden...

SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST PR Newswire SALT LAKE CITY , Feb. 1, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving mater...

SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX PR Newswire SALT LAKE CITY , Dec. 15, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregna...

Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth - New Assigned Rate Further Validates the Commercial Value of the PreTRM® Test - PR Newswire SALT LAKE CITY , Dec 2, 2021 /PRN...